NEW YORK — A research consortium led by Novigenix has received a Eurostars grant worth up to €1 million ($1.2 million) to develop a blood-based test to predict cancer patient responses to immune checkpoint inhibitors (ICIs), the Swiss molecular diagnostics firm said on Tuesday.
According to Novigenix, the consortium — which includes PamGene International and Radboud University — has already generated data predicting metastatic urothelial cancer patients' responses to anti-PD-1 checkpoint inhibitors.